Metformin for endometrial hyperplasia: a Cochrane protocol.
Metformin for endometrial hyperplasia: a Cochrane protocol.
复制标题
DOI：
10.1136/bmjopen-2016-013385
复制
发表时间：
2016-08-16
期刊：
影响因子：
2.9
通讯作者：
Atiomo W
中科院分区：
文献类型：
--
作者：
Clement NS;Oliver TR;Shiwani H;Saner JR;Mulvaney CA;Atiomo W
子宫内膜增生症是子宫内膜的癌前病变，通常表现为子宫出血。如果进行预期治疗，它经常进展为子宫内膜癌，其发病率在世界范围内急剧增加。然而，子宫内膜增生的既定治疗（孕激素）涉及多种副作用，并留下复发的风险。二甲双胍是2型糖尿病最常用的口服降糖药。它还与子宫内膜增生的逆转有关，因此可能有助于降低子宫内膜癌的患病率，而不会产生目前治疗的生育力和副作用后果。然而，二甲双胍用于该治疗目标的疗效和安全性尚不清楚，因此，本系统性综述旨在确定这一点。我们将检索以下试验和数据库，无语言限制：科克伦妇科和生育专业注册库;科克伦对照试验中心注册库（CENTRAL）; MEDLINE; EMBASE; EBSCO护理和相关健康文献累积索引; PubMed; Google Scholar; ClinicalTrials.gov; WHO国际试验注册平台门户; OpenGrey和拉丁美洲和加勒比健康科学文献（LILACS）。我们将纳入使用二甲双胍与安慰剂或不治疗、常规药物治疗（如孕激素）或任何其他积极干预相比的随机对照试验（RCT）。两名综述作者将独立评估试验合格性、偏倚风险并提取适当的数据点。将联系试验作者获取更多数据。主要审查结果是子宫内膜增生组织学向正常组织学的回归。次要结果包括子宫切除率、异常子宫出血、生活质量评分和治疗不良反应。完成的综述将通过科克伦图书馆以及在适当的会议上介绍结果进行传播。
Endometrial hyperplasia is a precancerous lesion of the endometrium, commonly presenting with uterine bleeding. If managed expectantly, it frequently progresses to endometrial carcinoma, rates of which are increasing dramatically worldwide. However, the established treatment for endometrial hyperplasia (progestogens) involves multiple side effects and leaves the risk of recurrence. Metformin is the most commonly used oral hypoglycaemic agent in type 2 diabetes mellitus. It has also been linked to the reversal of endometrial hyperplasia and may therefore contribute to decreasing the prevalence of endometrial carcinoma without the fertility and side effect consequences of current therapies. However, the efficacy and safety of metformin being used for this therapeutic target is unclear and, therefore, this systematic review will aim to determine this. We will search the following trials and databases with no language restrictions: Cochrane Gynaecology and Fertility Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; EBSCO Cumulative Index to Nursing and Allied Health Literature; PubMed; Google Scholar; ClinicalTrials.gov; the WHO International Trials Registry Platform portal; OpenGrey and the Latin American and Caribbean Health Sciences Literature (LILACS). We will include randomised controlled trials (RCTs) of use of metformin compared with a placebo or no treatment, conventional medical treatment (eg, progestogens) or any other active intervention. Two review authors will independently assess the trial eligibility, risk of bias and extract appropriate data points. Trial authors will be contacted for additional data. The primary review outcome is the regression of endometrial hyperplasia histology towards normal histology. Secondary outcomes include hysterectomy rate; abnormal uterine bleeding; quality of life scores and adverse reactions to treatments. Dissemination of the completed review will be through the Cochrane Library as well as through presenting the results at appropriate conferences.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
7.2
作者：
Torres ML;Weaver AL;Kumar S;Uccella S;Famuyide AO;Cliby WA;Dowdy SC;Gostout BS;Mariani A
通讯作者：
Mariani A
影响因子：
6.1
作者：
Haoula, Zeina;Salman, Maisa;Atiomo, William
通讯作者：
Atiomo, William
黄体酮：最终的子宫内膜肿瘤抑制剂。
影响因子：
10.9
作者：
Yang, Shujie;Thiel, Kristina W.;Leslie, Kimberly K.
通讯作者：
Leslie, Kimberly K.
DOI：
10.1136/bmj.c2181
发表时间：
2010-05-20
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
de Jager J;Kooy A;Lehert P;Wulffelé MG;van der Kolk J;Bets D;Verburg J;Donker AJ;Stehouwer CD
通讯作者：
Stehouwer CD